Orion Corporation Share Conversion Update
ORION CORPORATION
STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE
Orion Corporation has recently announced a significant update regarding its share structure. A total of 79,345 A shares have been successfully converted into B shares, processed in accordance with Section 3 of the Articles of Association.
Details of the Conversion
This noteworthy conversion has been recorded in the Trade Register. Following the change, the total share count of Orion Corporation stands at 141,134,278 shares. The new distribution includes 32,752,263 A shares and 108,382,015 B shares, impacting the overall voting rights associated with these shares.
Impact on Voting Rights
After the recent conversion, the voting power derived from Orion's shares amounts to 763,427,275 votes. This modification is crucial as it can influence decision-making processes within the company, particularly in shareholder meetings.
Company Leadership
Orion Corporation is steered by experienced leaders who play vital roles in the company's strategy and operations. We highlight two key figures within the organization:
René Lindell, Chief Financial Officer, spearheads the financial initiatives, while Olli Huotari serves as the Senior Vice President of Corporate Functions, overseeing various essential elements of operations.
Contact Information
For further inquiries and details, you can reach out to Tuukka Hirvonen from the Investor Relations team at Orion Corporation. He is available at +358 10 426 2721.
About Orion Corporation
Orion is a Finnish pharmaceutical company with a rich history of over a century dedicated to wellness. The company focuses on developing, manufacturing, and marketing both human and veterinary pharmaceuticals, along with active pharmaceutical ingredients. Orion's robust portfolio includes a range of proprietary and generic medicines, as well as consumer health products.
Research and Development Focus
Orion's research and development efforts are concentrated in key therapeutic areas such as oncology and pain management. Their proprietary products are designed to address various critical health issues including cancer, neurological disorders, and respiratory conditions.
Performance Highlights
As of the end of the last year, Orion reported impressive net sales of EUR 1,190 million. The company boasted a workforce of approximately 3,600 employees, accentuating its capacity for innovation and market presence.
Stock Information
The company's shares, categorized into A and B classes, are actively traded on Nasdaq Helsinki under the ticker symbol ORNBV. This provides investors with a unique opportunity to be part of Orion's continuous growth and commitment to enhancing health outcomes.
Frequently Asked Questions
What is the significance of the share conversion?
The conversion of A shares into B shares affects the overall distribution and voting rights within Orion Corporation, potentially influencing decision-making within the company.
Who can I contact for more information regarding Orion Corporation?
For inquiries, you can contact Tuukka Hirvonen at +358 10 426 2721, who is in charge of Investor Relations.
What areas does Orion's R&D focus on?
Orion focuses its research and development efforts on oncology and pain, among other therapeutic areas, enhancing their pharmaceutical offerings.
How many shares are currently outstanding for Orion Corporation?
The total number of shares after the conversion stands at 141,134,278 A and B shares combined.
Where is Orion Corporation listed?
Orion Corporation's A and B shares are listed on Nasdaq Helsinki, under the ticker symbol ORNBV.
